State Farm Mutual Automobile Insurance Co. held its stake in C.R. Bard, Inc. (NYSE:BCR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 59,005 shares of the medical instruments supplier’s stock at the end of the second quarter. State Farm Mutual Automobile Insurance Co. owned approximately 0.08% of C.R. Bard worth $18,652,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. SRS Capital Advisors Inc. grew its position in shares of C.R. Bard by 0.7% during the 1st quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 4 shares during the period. Alps Advisors Inc. grew its position in C.R. Bard by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 1,921 shares of the medical instruments supplier’s stock valued at $607,000 after purchasing an additional 5 shares during the period. Parallel Advisors LLC grew its position in C.R. Bard by 2.8% in the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after purchasing an additional 14 shares during the period. Blair William & Co. IL grew its position in C.R. Bard by 0.9% in the 1st quarter. Blair William & Co. IL now owns 3,492 shares of the medical instruments supplier’s stock valued at $865,000 after purchasing an additional 30 shares during the period. Finally, First Merchants Corp grew its position in C.R. Bard by 0.6% in the 2nd quarter. First Merchants Corp now owns 5,135 shares of the medical instruments supplier’s stock valued at $1,623,000 after purchasing an additional 32 shares during the period. Hedge funds and other institutional investors own 79.34% of the company’s stock.
A number of equities analysts have issued reports on BCR shares. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 target price on the stock in a research note on Tuesday, June 6th. BidaskClub cut C.R. Bard from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. BMO Capital Markets restated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a research note on Tuesday, July 11th. Finally, Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $285.67.
Shares of C.R. Bard, Inc. (NYSE BCR) traded down 0.10% during mid-day trading on Friday, reaching $320.20. The company’s stock had a trading volume of 191,800 shares. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $324.58. The company’s 50-day moving average price is $320.21 and its 200-day moving average price is $296.89. The stock has a market capitalization of $23.27 billion, a P/E ratio of 42.04 and a beta of 0.60.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The company had revenue of $979.70 million for the quarter, compared to analysts’ expectations of $976.53 million. During the same period last year, the firm earned $2.54 earnings per share. C.R. Bard’s quarterly revenue was up 5.2% on a year-over-year basis. On average, equities research analysts forecast that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/state-farm-mutual-automobile-insurance-co-has-18652000-holdings-in-c-r-bard-inc-bcr/1602657.html.
In related news, insider John P. Groetelaars sold 23,687 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the transaction, the insider now owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.80% of the stock is currently owned by insiders.
C.R. Bard Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with our FREE daily email newsletter.